Published in Gut on February 08, 2011
Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer (2015) 2.67
Regulation of hepatic innate immunity by hepatitis C virus. Nat Med (2013) 1.93
Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection. Gastroenterology (2012) 1.80
Suppression of interferon lambda signaling by SOCS-1 results in their excessive production during influenza virus infection. PLoS Pathog (2014) 1.59
The genetic theory of infectious diseases: a brief history and selected illustrations. Annu Rev Genomics Hum Genet (2013) 1.17
Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther (2013) 1.15
Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog (2013) 1.07
Innate immune responses in hepatitis C virus infection. Semin Immunopathol (2012) 1.06
Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol (2011) 1.04
Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease. Hepat Mon (2012) 0.98
Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol (2013) 0.96
The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect (2014) 0.96
Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. Gut (2014) 0.94
Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol (2015) 0.91
Innate host responses to West Nile virus: Implications for central nervous system immunopathology. World J Virol (2013) 0.91
IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. PLoS Pathog (2014) 0.89
IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2011) 0.86
Hepatitis C virus: current concepts and future challenges. QJM (2011) 0.85
High levels of β-catenin promote IFNγ-induced apoptosis in hepatocellular carcinoma cells. Oncol Lett (2012) 0.83
Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. J Immunol Res (2015) 0.82
The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Clin Dev Immunol (2012) 0.81
Hepatitis C Virus. Strategies to Evade Antiviral Responses. Future Virol (2015) 0.81
Comparison of the regulation of β-catenin signaling by type I, type II and type III interferons in hepatocellular carcinoma cells. PLoS One (2012) 0.79
Characterization of the Interleukin-28B Gene rs12979860 C/T Polymorphism in Turkish Chronic Hepatitis C Patients and Healthy Individuals. Balkan Med J (2015) 0.79
Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions. J Interferon Cytokine Res (2014) 0.78
Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war? World J Gastroenterol (2015) 0.78
Computational models of the JAK1/2-STAT1 signaling. JAKSTAT (2013) 0.78
Evaluation of IL-28B polymorphisms and serum IP-10 in hepatitis C infected chimpanzees. PLoS One (2012) 0.77
Insights into antiviral innate immunity revealed by studying hepatitis C virus. Cytokine (2015) 0.76
The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy. J Immunol Res (2017) 0.75
The Associations of HLA-A*02:01 and DRB1*11:01 with Hepatitis C Virus Spontaneous Clearance Are Independent of IL28B in the Chinese Population. Sci Rep (2016) 0.75
Recombinant adenovirus expressing hIFN-λ1 inhibits gastric adenocarcinoma cell line SGC-7901 proliferation. Oncol Lett (2015) 0.75
Impact of Interleukin 28B Genotype on the Virological Responses in Chronic Hepatitis C Treatment. Gastroenterology Res (2014) 0.75
IFN-λ: A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research. Gastroenterol Res Pract (2015) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Rare variants create synthetic genome-wide associations. PLoS Biol (2010) 14.43
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A (1998) 13.39
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87
IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22
Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet (2010) 9.53
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A (2008) 8.56
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med (2004) 8.12
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med (1999) 6.50
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16
Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med (2006) 5.90
Lambda interferon inhibits hepatitis B and C virus replication. J Virol (2005) 5.47
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol (2006) 4.21
Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology (2006) 3.46
Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology (2010) 3.26
Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol (2004) 3.25
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology (2010) 2.87
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83
IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol (2005) 2.63
Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem (2004) 2.55
Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol (2003) 2.10
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 2.02
Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem (1996) 1.92
Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun (2009) 1.81
Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood (2006) 1.76
Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem (2009) 1.73
Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun (2007) 1.60
Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology (1999) 1.59
Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology (2009) 1.58
Interferon type I gene expression in chronic hepatitis C. Lab Invest (2004) 1.55
Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem (2008) 1.32
Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis (2010) 1.28
Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol (2008) 1.26
IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood (2009) 1.15
IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther (2010) 1.12
Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope. Hepatology (2010) 1.11
Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology (2008) 1.10
Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus. J Interferon Cytokine Res (2010) 0.94
IL-4 enhances IFN-lambda1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra. Blood (2010) 0.90
Interleukin-28 and interleukin-29: novel regulators of skin biology. J Interferon Cytokine Res (2010) 0.88
[IL28 (interferon lambda3) gene polymorphisms and response to IFN-alpha treatment in patients infected with hepatitis virus C]. Med Sci (Paris) (2010) 0.81
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Genome-wide genetic association of complex traits in heterogeneous stock mice. Nat Genet (2006) 9.87
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med (2012) 3.99
Global distribution and prevalence of hepatitis C virus genotypes. Hepatology (2014) 3.95
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol (2003) 3.02
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 2.77
Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis (2008) 2.64
T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet (2005) 2.41
Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol (2007) 2.40
Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol (2006) 2.25
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol (2005) 2.24
Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology (2003) 2.23
Genetic history of hepatitis C virus in East Asia. J Virol (2008) 2.20
Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A (2010) 2.19
Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol (2005) 2.14
Evolution of diverse antiviral CD8+ T cell populations after murine cytomegalovirus infection. Eur J Immunol (2005) 2.12
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 2.03
High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol (2007) 2.01
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology (2006) 1.96
A protocol for high-throughput phenotyping, suitable for quantitative trait analysis in mice. Mamm Genome (2006) 1.96
CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol (2012) 1.95
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med (2012) 1.94
Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol (2005) 1.94
Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology (2009) 1.88
Ex vivo characterization of early secretory antigenic target 6-specific T cells at sites of active disease in pleural tuberculosis. Clin Infect Dis (2004) 1.88
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells. Blood (2011) 1.83
Development of novel treatments for hepatitis C. Lancet Infect Dis (2009) 1.80
High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis (2009) 1.78
Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut (2010) 1.77
Dynamic coinfection with multiple viral subtypes in acute hepatitis C. J Infect Dis (2010) 1.75
CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. Eur J Immunol (2013) 1.72
Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J Immunol (2004) 1.64
Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol (2005) 1.62
Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection. Blood (2012) 1.60
Commercially available outbred mice for genome-wide association studies. PLoS Genet (2010) 1.58
The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology (2002) 1.57
Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J Virol (2004) 1.55
HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory. Virology (2006) 1.54
Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol (2005) 1.54
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology (2009) 1.54
Prolonged activation of virus-specific CD8+T cells after acute B19 infection. PLoS Med (2005) 1.53
The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood (2004) 1.53
Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut (2010) 1.53
Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. J Clin Virol (2007) 1.49
Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells. J Virol (2004) 1.48
Transient CD8-memory contraction: a potential contributor to latent cytomegalovirus reactivation. J Leukoc Biol (2012) 1.47
Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. J Virol (2007) 1.46
Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest (2009) 1.46
HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS (2010) 1.45
Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J Virol (2006) 1.45
Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology (2009) 1.44
Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology (2005) 1.44
Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol (2007) 1.41
Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol (2002) 1.40
HIV/AIDS. HLA leaves its footprints on HIV. Science (2002) 1.39
Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines (2011) 1.37
HLA footprints on human immunodeficiency virus type 1 are associated with interclade polymorphisms and intraclade phylogenetic clustering. J Virol (2009) 1.30
CD161 expression on hepatitis C virus-specific CD8+ T cells suggests a distinct pathway of T cell differentiation. Hepatology (2008) 1.30
Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology (2011) 1.30
Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution. J Virol (2009) 1.29
The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology (2009) 1.29
Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol (2008) 1.28
Effects of promyelocytic leukemia protein on virus-host balance. J Virol (2002) 1.28
B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun (2010) 1.26
High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol (2004) 1.25
Progression to AIDS in South Africa is associated with both reverting and compensatory viral mutations. PLoS One (2011) 1.24
Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. Eur J Immunol (2004) 1.24
The impact of differential antiviral immunity in children and adults. Nat Rev Immunol (2012) 1.21
Unique acquisition of cytotoxic T-lymphocyte escape mutants in infant human immunodeficiency virus type 1 infection. J Virol (2005) 1.20
The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos. Trans R Soc Trop Med Hyg (2010) 1.20
Report from the second cytomegalovirus and immunosenescence workshop. Immun Ageing (2011) 1.19
Properties of murine (CD8+)CD27- T cells. Eur J Immunol (2005) 1.19
Viral coinfections among African children infected with human immunodeficiency virus type 1. Clin Infect Dis (2003) 1.18
Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro. Hepatology (2010) 1.17
Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One (2007) 1.16
Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection. J Virol (2003) 1.16
Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther (2013) 1.15
HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. J Clin Invest (2005) 1.15
Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success. Proc Natl Acad Sci U S A (2003) 1.15
A novel method for autophagy detection in primary cells: impaired levels of macroautophagy in immunosenescent T cells. Autophagy (2012) 1.15